Loading…
Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age
Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 1...
Saved in:
| Published in: | Vaccine 2009-02, Vol.27 (9), p.1333-1339 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3 |
| container_end_page | 1339 |
| container_issue | 9 |
| container_start_page | 1333 |
| container_title | Vaccine |
| container_volume | 27 |
| creator | Zaman, K Sack, D.A Yunus, M Arifeen, S.E Podder, G Azim, T Luby, S Breiman, R.F Neuzil, K Datta, S.K Delem, A Suryakiran, P.V Bock, H.L |
| description | Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5–66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates. |
| doi_str_mv | 10.1016/j.vaccine.2008.12.059 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66934468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X09000024</els_id><sourcerecordid>20397225</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3</originalsourceid><addsrcrecordid>eNqFkk1vEzEQhlcIREPhJ4AsIXrb4LF3HfsCgoovqRKHgsTNcrzjxunGTu3dVP0f_GCcZEWlXnqyxnrmnY93quo10DlQEO_X852x1gecM0rlHNictupJNQO54DVrQT6tZpSJpm6A_jmpXuS8ppS2HNTz6gQUCAbQzKq_l6O1mLMbe2JjbbqNDz4PyQw-BhIdMWQ1bkwgKQ5m59OYiQkdicn0ZBt7H49_Uy-Z-EA-m3DVmw7zypfQmTAcvg1hdRczkmxX2I09EjMQYAc5EOQW8TofCl7hy-qZM33GV9N7Wv3--uXX-ff64ue3H-efLmrb0sVQCyW5EA3IVnEEVSJqpVu6EgjjwBiGopGuLEF23LWqWXbLhjkAixwWbslPq7Oj7jbFmxHzoDc-W-x7EzCOWQuheNMI-SjIKFcLxtoCvn0AruOYQhlCgwApOTCghWqPlE0x54ROb5PfmHSngeq9u3qtp43qvbsamC7ulrw3k_q43GB3nzXZWYB3E2CyNb1LJlif_3MMmFSw2Lf58chh2e7OY9LZegwWO5_QDrqL_tFWPjxQsH25nFL0Gu8w30-tc0nQl_tT3F8iVeUKKWv4P_S22bo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618831210</pqid></control><display><type>article</type><title>Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Zaman, K ; Sack, D.A ; Yunus, M ; Arifeen, S.E ; Podder, G ; Azim, T ; Luby, S ; Breiman, R.F ; Neuzil, K ; Datta, S.K ; Delem, A ; Suryakiran, P.V ; Bock, H.L</creator><creatorcontrib>Zaman, K ; Sack, D.A ; Yunus, M ; Arifeen, S.E ; Podder, G ; Azim, T ; Luby, S ; Breiman, R.F ; Neuzil, K ; Datta, S.K ; Delem, A ; Suryakiran, P.V ; Bock, H.L ; the Bangladeshi Rotavirus Vaccine study group ; Bangladeshi Rotavirus Vaccine study group</creatorcontrib><description>Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5–66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2008.12.059</identifier><identifier>PMID: 19162114</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Administration, Oral ; Age ; Allergy and Immunology ; Antibodies, Viral - blood ; Antibody Formation ; Applied microbiology ; Bangladesh - epidemiology ; Biological and medical sciences ; Children & youth ; Confidence intervals ; Developing countries ; Diarrhea - epidemiology ; Diarrhea - immunology ; Diarrhea - virology ; Double-Blind Method ; Drug Administration Schedule ; Female ; Fundamental and applied biological sciences. Psychology ; Gastroenteritis - epidemiology ; Gastroenteritis - etiology ; Gastroenteritis - immunology ; Gastrointestinal disease ; Human rotavirus ; Humans ; Immunization ; Infant ; LDCs ; Male ; Microbiology ; Miscellaneous ; Nutrition research ; Oral poliovirus ; Poliomyelitis - immunology ; Poliovirus ; Poliovirus Vaccines - administration & dosage ; Poliovirus Vaccines - therapeutic use ; Rotavirus ; Rotavirus Infections - epidemiology ; Rotavirus Infections - immunology ; Rotavirus Vaccines - administration & dosage ; Rotavirus Vaccines - therapeutic use ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Virology ; Viruses</subject><ispartof>Vaccine, 2009-02, Vol.27 (9), p.1333-1339</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Elsevier Limited Feb 25, 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3</citedby><cites>FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21289175$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19162114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaman, K</creatorcontrib><creatorcontrib>Sack, D.A</creatorcontrib><creatorcontrib>Yunus, M</creatorcontrib><creatorcontrib>Arifeen, S.E</creatorcontrib><creatorcontrib>Podder, G</creatorcontrib><creatorcontrib>Azim, T</creatorcontrib><creatorcontrib>Luby, S</creatorcontrib><creatorcontrib>Breiman, R.F</creatorcontrib><creatorcontrib>Neuzil, K</creatorcontrib><creatorcontrib>Datta, S.K</creatorcontrib><creatorcontrib>Delem, A</creatorcontrib><creatorcontrib>Suryakiran, P.V</creatorcontrib><creatorcontrib>Bock, H.L</creatorcontrib><creatorcontrib>the Bangladeshi Rotavirus Vaccine study group</creatorcontrib><creatorcontrib>Bangladeshi Rotavirus Vaccine study group</creatorcontrib><title>Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5–66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.</description><subject>Administration, Oral</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody Formation</subject><subject>Applied microbiology</subject><subject>Bangladesh - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Children & youth</subject><subject>Confidence intervals</subject><subject>Developing countries</subject><subject>Diarrhea - epidemiology</subject><subject>Diarrhea - immunology</subject><subject>Diarrhea - virology</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastroenteritis - epidemiology</subject><subject>Gastroenteritis - etiology</subject><subject>Gastroenteritis - immunology</subject><subject>Gastrointestinal disease</subject><subject>Human rotavirus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>LDCs</subject><subject>Male</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Nutrition research</subject><subject>Oral poliovirus</subject><subject>Poliomyelitis - immunology</subject><subject>Poliovirus</subject><subject>Poliovirus Vaccines - administration & dosage</subject><subject>Poliovirus Vaccines - therapeutic use</subject><subject>Rotavirus</subject><subject>Rotavirus Infections - epidemiology</subject><subject>Rotavirus Infections - immunology</subject><subject>Rotavirus Vaccines - administration & dosage</subject><subject>Rotavirus Vaccines - therapeutic use</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Virology</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkk1vEzEQhlcIREPhJ4AsIXrb4LF3HfsCgoovqRKHgsTNcrzjxunGTu3dVP0f_GCcZEWlXnqyxnrmnY93quo10DlQEO_X852x1gecM0rlHNictupJNQO54DVrQT6tZpSJpm6A_jmpXuS8ppS2HNTz6gQUCAbQzKq_l6O1mLMbe2JjbbqNDz4PyQw-BhIdMWQ1bkwgKQ5m59OYiQkdicn0ZBt7H49_Uy-Z-EA-m3DVmw7zypfQmTAcvg1hdRczkmxX2I09EjMQYAc5EOQW8TofCl7hy-qZM33GV9N7Wv3--uXX-ff64ue3H-efLmrb0sVQCyW5EA3IVnEEVSJqpVu6EgjjwBiGopGuLEF23LWqWXbLhjkAixwWbslPq7Oj7jbFmxHzoDc-W-x7EzCOWQuheNMI-SjIKFcLxtoCvn0AruOYQhlCgwApOTCghWqPlE0x54ROb5PfmHSngeq9u3qtp43qvbsamC7ulrw3k_q43GB3nzXZWYB3E2CyNb1LJlif_3MMmFSw2Lf58chh2e7OY9LZegwWO5_QDrqL_tFWPjxQsH25nFL0Gu8w30-tc0nQl_tT3F8iVeUKKWv4P_S22bo</recordid><startdate>20090225</startdate><enddate>20090225</enddate><creator>Zaman, K</creator><creator>Sack, D.A</creator><creator>Yunus, M</creator><creator>Arifeen, S.E</creator><creator>Podder, G</creator><creator>Azim, T</creator><creator>Luby, S</creator><creator>Breiman, R.F</creator><creator>Neuzil, K</creator><creator>Datta, S.K</creator><creator>Delem, A</creator><creator>Suryakiran, P.V</creator><creator>Bock, H.L</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090225</creationdate><title>Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age</title><author>Zaman, K ; Sack, D.A ; Yunus, M ; Arifeen, S.E ; Podder, G ; Azim, T ; Luby, S ; Breiman, R.F ; Neuzil, K ; Datta, S.K ; Delem, A ; Suryakiran, P.V ; Bock, H.L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Oral</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody Formation</topic><topic>Applied microbiology</topic><topic>Bangladesh - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Children & youth</topic><topic>Confidence intervals</topic><topic>Developing countries</topic><topic>Diarrhea - epidemiology</topic><topic>Diarrhea - immunology</topic><topic>Diarrhea - virology</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastroenteritis - epidemiology</topic><topic>Gastroenteritis - etiology</topic><topic>Gastroenteritis - immunology</topic><topic>Gastrointestinal disease</topic><topic>Human rotavirus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>LDCs</topic><topic>Male</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Nutrition research</topic><topic>Oral poliovirus</topic><topic>Poliomyelitis - immunology</topic><topic>Poliovirus</topic><topic>Poliovirus Vaccines - administration & dosage</topic><topic>Poliovirus Vaccines - therapeutic use</topic><topic>Rotavirus</topic><topic>Rotavirus Infections - epidemiology</topic><topic>Rotavirus Infections - immunology</topic><topic>Rotavirus Vaccines - administration & dosage</topic><topic>Rotavirus Vaccines - therapeutic use</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaman, K</creatorcontrib><creatorcontrib>Sack, D.A</creatorcontrib><creatorcontrib>Yunus, M</creatorcontrib><creatorcontrib>Arifeen, S.E</creatorcontrib><creatorcontrib>Podder, G</creatorcontrib><creatorcontrib>Azim, T</creatorcontrib><creatorcontrib>Luby, S</creatorcontrib><creatorcontrib>Breiman, R.F</creatorcontrib><creatorcontrib>Neuzil, K</creatorcontrib><creatorcontrib>Datta, S.K</creatorcontrib><creatorcontrib>Delem, A</creatorcontrib><creatorcontrib>Suryakiran, P.V</creatorcontrib><creatorcontrib>Bock, H.L</creatorcontrib><creatorcontrib>the Bangladeshi Rotavirus Vaccine study group</creatorcontrib><creatorcontrib>Bangladeshi Rotavirus Vaccine study group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaman, K</au><au>Sack, D.A</au><au>Yunus, M</au><au>Arifeen, S.E</au><au>Podder, G</au><au>Azim, T</au><au>Luby, S</au><au>Breiman, R.F</au><au>Neuzil, K</au><au>Datta, S.K</au><au>Delem, A</au><au>Suryakiran, P.V</au><au>Bock, H.L</au><aucorp>the Bangladeshi Rotavirus Vaccine study group</aucorp><aucorp>Bangladeshi Rotavirus Vaccine study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2009-02-25</date><risdate>2009</risdate><volume>27</volume><issue>9</issue><spage>1333</spage><epage>1339</epage><pages>1333-1339</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>ObjectType-Article-2</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-News-3</notes><abstract>Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 ( Rotarix ™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5–66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>19162114</pmid><doi>10.1016/j.vaccine.2008.12.059</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2009-02, Vol.27 (9), p.1333-1339 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66934468 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Administration, Oral Age Allergy and Immunology Antibodies, Viral - blood Antibody Formation Applied microbiology Bangladesh - epidemiology Biological and medical sciences Children & youth Confidence intervals Developing countries Diarrhea - epidemiology Diarrhea - immunology Diarrhea - virology Double-Blind Method Drug Administration Schedule Female Fundamental and applied biological sciences. Psychology Gastroenteritis - epidemiology Gastroenteritis - etiology Gastroenteritis - immunology Gastrointestinal disease Human rotavirus Humans Immunization Infant LDCs Male Microbiology Miscellaneous Nutrition research Oral poliovirus Poliomyelitis - immunology Poliovirus Poliovirus Vaccines - administration & dosage Poliovirus Vaccines - therapeutic use Rotavirus Rotavirus Infections - epidemiology Rotavirus Infections - immunology Rotavirus Vaccines - administration & dosage Rotavirus Vaccines - therapeutic use Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology Viruses |
| title | Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T09%3A40%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20co-administration%20of%20a%20human%20rotavirus%20and%20oral%20poliovirus%20vaccines%20in%20Bangladeshi%20infants%20in%20a%202-dose%20schedule%20at%2012%20and%2016%20weeks%20of%20age&rft.jtitle=Vaccine&rft.au=Zaman,%20K&rft.aucorp=the%20Bangladeshi%20Rotavirus%20Vaccine%20study%20group&rft.date=2009-02-25&rft.volume=27&rft.issue=9&rft.spage=1333&rft.epage=1339&rft.pages=1333-1339&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2008.12.059&rft_dat=%3Cproquest_cross%3E20397225%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c507t-698366418593e199830c8fbf3e16af1aa2e648f2648d3f594bdb42f11ce317fb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1618831210&rft_id=info:pmid/19162114&rfr_iscdi=true |